Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07713901 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Name: Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma — clinical trial record (NCT07713901)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusEnrolling by Invitation

PhaseNot specified

SponsorNovo Nordisk A/S

Started2025-12-31

View on ClinicalTrials.gov ↗

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Amendment record

Amended once since 2026-07-15. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-03

Amendment Study Status v1

2026-07-15

Original filing

Trial Details

NCT Number	NCT07713901
Lead Sponsor	Novo Nordisk A/S
Conditions	Medullary Thyroid Carcinoma
Enrollment	93,600,000 participants
Start Date	2025-12-31
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-04